The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
MGC Pharmaceuticals boosted by UK import approval
CannEpil+ will be made available for free on compassionate grounds to ten patients with refractory epilepsy for six months, as part of a trial.
MGC Pharmaceuticals Ltd - MGC Pharmaceuticals boosted by UK import approval
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, FRA:H5O, ASX:MXC) is boosted by a new landmark as CannEpil+, a Cannabis based treatment for epilepsy, has been approved for import by the UK authorities.
An import permit was issued by the Medicines and Healthcare products Regulatory Agency, and, the award was enabled by MGC’s UK distribution and clinical access partner Elite Pharmaco.
It is the first time that an epilepsy treatment currently in a Clinical Trial process, and containing THC, has been approved by the authorities in the UK for import, MGC highlighted.
The company noted that the permit opens a new key strategic market for its leading phytocannabinoid derived medicine.
CannEpil+ will be made available for free on compassionate grounds to ten patients with refractory epilepsy for six months. The treatment will be monitored using a data collection app which will provide real time insights into the efficacy of CannEpil +.
Epilepsy is seen as one of the most common serious neurological conditions, affecting around 600,000 people in the UK (50mln worldwide) – and around 33% of adults, 20-25% of children, suffer from refractory epilepsy (otherwise known as drug resistant epilepsy) which cannot be controlled with traditional anti-seizure medication, MGC noted.
Wow very good news!! ??
NEWS OUT SOON!!!
Now is the time to top up. Tmrw we will see the blue sky. Big boys are topping up.
Load up, this will fly this week. News due in the next few days!!!
Back to 10p plus!!
First few trades in. Lovely jubbly.
HealthCannabisProactive07:37 Mon 01 Mar 2021viewFastForward Innovations LimitedFastForward Innovations bags a small slice of IPO success Cellular GoodsThe heavily over-subscribed offer of stock was completed at 5p a share. Cellular ended its first day of trading at 19pFastForward Innovations Limited - FastForward Innovations Ltd (LON:FFWD) said it has invested £17,215 in the £13mln IPO share placing by the David Beckham-backed Cellular Goods PLC (LON:CBX).The heavily over-subscribed offer of stock was completed at 5p a share. Cellular ended its first day at 19p.FastForward describes itself as an investor in “fast-growing and innovative businesses”. Cellular is creating skincare and athletic recovery products from biosynthetic cannabinoids.FastForward chief executive Ed McDermott said: "We are pleased to see another CBD wellness company IPO here in London.“Once again, the allocations were disappointing due to a significantly oversubscribed book.“However, we are very excited that the London Stock Exchange is fast becoming a destination for both medical cannabis and over the counter cannabinoid wellness companies."
Another red week down to the fifty's
Time to off load and wait for the drop.
Buy Buy Buy
https://www.telegraph.co.uk/global-health/science-and-disease/war-against-covid-arsenal-drugs-way/
Rise and shine sng!!!
Expansion of Glioblastoma research program
Mon, 15th Feb 2021 07:00
RNS Number : 0713P
MGC Pharmaceuticals Limited
15 February 2021
15 February 2021
ASX Code: MXC
LSE Code: MXC
New In-vitro cannabinoid study on Glioblastoma treatment using proprietary nano-delivery platform to commence
Key Highlights:
· MGC Pharma's research program into the use of cannabinoids in the treatment of aggressive glioblastoma brain cancer has been expanded, in collaboration with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre
· Preliminary results of MGC Pharma's proprietary cannabinoid treatment of Glioblastoma have recently completed an independent peer review and been formally published in the MDPI (Multidisciplinary Digital Publishing Institute) Medical Journal
· The new, expanded study will also explore the use of a nanoparticle delivery system to improve the effects of the glioblastoma treatment
· Delivery system is similar to the nanoparticle delivery system being used successfully in MGC Pharma's ArtemiCTM clinical trial into the treatment of COVID-19
· In-vitro results to date show that MGC Pharma formulated cannabigerol (CBG) can eliminate therapy-resistant glioblastoma stem cells
· Successful study results would mean a key breakthrough for MGC Pharma in the treatment of aggressive brain cancers, one of its key target clinical research treatment areas - Oncology
· The new study will shortly commence recruitment of new patients with grade IV glioblastomas to be divided into subcategories to receive a personalised treatment plan
MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce its ongoing pre-clinical research program ('Study') into Glioblastoma Multiforme ('GBM'), has significantly progressed and has now been expanded to explore the use of nano technology in relation to the most effective treatment delivery systems. GBM is the most aggressive and, to date, therapeutically resistant primary brain tumour.
This important GBM research program is being conducted in collaboration with MGC Phar
Rise and Shine!!!
https://**********.brand.live/c/vox-markets-and-turner-pope-webinar-friday-february-12th
Link to webinar
Take Off!!!
Little gem this company
Destiny Pharma to present at 14th Annual European Life Sciences CEO Forum, 10 – 11 March 2021
Destiny Pharma is presenting at the 14th Annual European Life Sciences CEO Forum on 10 – 11 March 2021.
If you would like to meet virtually with Destiny Pharma, please email us on conferences@destinypharma.com
Big boys have access to such events. Come on Destiny :)